Search Results

You are looking at 131 - 140 of 448 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Charu Aggarwal, Neeta Somaiah, and George R. Simon

survival than those without acne-like rash ( P < .001). 48 Therefore, the presence of rash seems to be the best predictor of clinical benefit for patients treated with cetuximab. In a similarly designed BMS-099 trial that compared carboplatin/paclitaxel

Full access

Noa Efrat Ben-Baruch, Ron Bose, Shyam M. Kavuri, Cynthia X. Ma, and Matthew J. Ellis

for HER2 -mutated breast cancer should be considered in the future. Phase I trials of neratinib with paclitaxel, capecitabine, or vinorelbine have demonstrated that these combinations are safe 8 – 10 ; neratinib has also been combined with other

Full access

Lauren Nye, Timothy K. Huyck, and William J. Gradishar

count recovery before delivery. After delivery, the patient will be offered paclitaxel therapy every 2 weeks for 4 doses followed by surgical management. Both breast-conserving therapy and mastectomy were discussed with patient. Genetic testing was

Full access

,040 cGy will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50 mg/m 2 ) for 6 weeks, followed by surgery. FTD/TPI will be self-administered (in tablet form) twice daily by study participants and

Full access

will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50 mg/m2) for 6 weeks, followed by surgery. FTD/TPI will be self-administered (in tablet form) twice daily by study participants and documented in

Full access

/TPI (35 mg/m 2 twice daily) and oxaliplatin (85 mg/m 2 ) before undergoing concurrent chemoradiation (standard-of-care radiation dose of 5,040 cGy will be used at all participating study sites) with carboplatin (area under the curve 2) and paclitaxel (50

Full access

Presenter: Deborah K. Armstrong

The study’s first arm was placebo + carboplatin/paclitaxel followed by placebo as maintenance. Arm 2 was veliparib + carboplatin/paclitaxel followed by placebo. Arm 3 was veliparib + carboplatin/paclitaxel followed by veliparib maintenance. An

Full access

/TPI (35 mg/m 2 twice daily) and oxaliplatin (85 mg/m 2 ) before undergoing concurrent chemoradiation (standard-of-care radiation dose of 5,040 cGy will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50

Full access

dose of 5,040 cGy will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50 mg/m2) for 6 weeks, followed by surgery. FTD/TPI will be self-administered (in tablet form) twice daily by study participants

Full access

Daniel Morgensztern and Ramaswamy Govindan

randomised controlled trial . Lancet Oncol 2006 ; 7 : 719 – 727 . 13. Strauss GM Herndon J Maddaus MA . Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung